Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Prophylactic Hiv Drug Market

ID: MRFR/HC/41661-HCR
200 Pages
Rahul Gotadki
Last Updated: April 24, 2026

Prophylactic HIV Drug Market Research Report: Size, Share, Trend Analysis By Drug Class (NRTIs, NNRTIs, PIs, Integrase Inhibitors), By Administration Route (Oral, Injection, Topical), By Applications Area (Pre-Exposure Prophylaxis, Post-Exposure Prophylaxis, Prevention in High-Risk Populations), By End Users (Hospitals, Clinics, Home Care Settings) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Prophylactic Hiv Drug Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Drug Class (USD Billion)
  49.     4.1.1 NRTIs
  50.     4.1.2 NNRTIs
  51.     4.1.3 PIs
  52.     4.1.4 Integrase Inhibitors
  53.   4.2 Healthcare, BY Administration Route (USD Billion)
  54.     4.2.1 Oral
  55.     4.2.2 Injection
  56.     4.2.3 Topical
  57.   4.3 Healthcare, BY Application Area (USD Billion)
  58.     4.3.1 Pre-Exposure Prophylaxis
  59.     4.3.2 Post-Exposure Prophylaxis
  60.     4.3.3 Prevention in High-Risk Populations
  61.   4.4 Healthcare, BY End User (USD Billion)
  62.     4.4.1 Hospitals
  63.     4.4.2 Clinics
  64.     4.4.3 Home Care Settings
  65.   4.5 Healthcare, BY Region (USD Billion)
  66.     4.5.1 North America
  67.       4.5.1.1 US
  68.       4.5.1.2 Canada
  69.     4.5.2 Europe
  70.       4.5.2.1 Germany
  71.       4.5.2.2 UK
  72.       4.5.2.3 France
  73.       4.5.2.4 Russia
  74.       4.5.2.5 Italy
  75.       4.5.2.6 Spain
  76.       4.5.2.7 Rest of Europe
  77.     4.5.3 APAC
  78.       4.5.3.1 China
  79.       4.5.3.2 India
  80.       4.5.3.3 Japan
  81.       4.5.3.4 South Korea
  82.       4.5.3.5 Malaysia
  83.       4.5.3.6 Thailand
  84.       4.5.3.7 Indonesia
  85.       4.5.3.8 Rest of APAC
  86.     4.5.4 South America
  87.       4.5.4.1 Brazil
  88.       4.5.4.2 Mexico
  89.       4.5.4.3 Argentina
  90.       4.5.4.4 Rest of South America
  91.     4.5.5 MEA
  92.       4.5.5.1 GCC Countries
  93.       4.5.5.2 South Africa
  94.       4.5.5.3 Rest of MEA
  95. 5 SECTION V: COMPETITIVE ANALYSIS
  96.   5.1 Competitive Landscape
  97.     5.1.1 Overview
  98.     5.1.2 Competitive Analysis
  99.     5.1.3 Market share Analysis
  100.     5.1.4 Major Growth Strategy in the Healthcare
  101.     5.1.5 Competitive Benchmarking
  102.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  103.     5.1.7 Key developments and growth strategies
  104.       5.1.7.1 New Product Launch/Service Deployment
  105.       5.1.7.2 Merger & Acquisitions
  106.       5.1.7.3 Joint Ventures
  107.     5.1.8 Major Players Financial Matrix
  108.       5.1.8.1 Sales and Operating Income
  109.       5.1.8.2 Major Players R&D Expenditure. 2023
  110.   5.2 Company Profiles
  111.     5.2.1 Gilead Sciences (US)
  112.       5.2.1.1 Financial Overview
  113.       5.2.1.2 Products Offered
  114.       5.2.1.3 Key Developments
  115.       5.2.1.4 SWOT Analysis
  116.       5.2.1.5 Key Strategies
  117.     5.2.2 ViiV Healthcare (GB)
  118.       5.2.2.1 Financial Overview
  119.       5.2.2.2 Products Offered
  120.       5.2.2.3 Key Developments
  121.       5.2.2.4 SWOT Analysis
  122.       5.2.2.5 Key Strategies
  123.     5.2.3 Bristol-Myers Squibb (US)
  124.       5.2.3.1 Financial Overview
  125.       5.2.3.2 Products Offered
  126.       5.2.3.3 Key Developments
  127.       5.2.3.4 SWOT Analysis
  128.       5.2.3.5 Key Strategies
  129.     5.2.4 Merck & Co. (US)
  130.       5.2.4.1 Financial Overview
  131.       5.2.4.2 Products Offered
  132.       5.2.4.3 Key Developments
  133.       5.2.4.4 SWOT Analysis
  134.       5.2.4.5 Key Strategies
  135.     5.2.5 Johnson & Johnson (US)
  136.       5.2.5.1 Financial Overview
  137.       5.2.5.2 Products Offered
  138.       5.2.5.3 Key Developments
  139.       5.2.5.4 SWOT Analysis
  140.       5.2.5.5 Key Strategies
  141.     5.2.6 AbbVie (US)
  142.       5.2.6.1 Financial Overview
  143.       5.2.6.2 Products Offered
  144.       5.2.6.3 Key Developments
  145.       5.2.6.4 SWOT Analysis
  146.       5.2.6.5 Key Strategies
  147.     5.2.7 Teva Pharmaceutical Industries (IL)
  148.       5.2.7.1 Financial Overview
  149.       5.2.7.2 Products Offered
  150.       5.2.7.3 Key Developments
  151.       5.2.7.4 SWOT Analysis
  152.       5.2.7.5 Key Strategies
  153.     5.2.8 Mylan (US)
  154.       5.2.8.1 Financial Overview
  155.       5.2.8.2 Products Offered
  156.       5.2.8.3 Key Developments
  157.       5.2.8.4 SWOT Analysis
  158.       5.2.8.5 Key Strategies
  159.   5.3 Appendix
  160.     5.3.1 References
  161.     5.3.2 Related Reports
  162. 6 LIST OF FIGURES
  163.   6.1 MARKET SYNOPSIS
  164.   6.2 NORTH AMERICA MARKET ANALYSIS
  165.   6.3 US MARKET ANALYSIS BY DRUG CLASS
  166.   6.4 US MARKET ANALYSIS BY ADMINISTRATION ROUTE
  167.   6.5 US MARKET ANALYSIS BY APPLICATION AREA
  168.   6.6 US MARKET ANALYSIS BY END USER
  169.   6.7 CANADA MARKET ANALYSIS BY DRUG CLASS
  170.   6.8 CANADA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  171.   6.9 CANADA MARKET ANALYSIS BY APPLICATION AREA
  172.   6.10 CANADA MARKET ANALYSIS BY END USER
  173.   6.11 EUROPE MARKET ANALYSIS
  174.   6.12 GERMANY MARKET ANALYSIS BY DRUG CLASS
  175.   6.13 GERMANY MARKET ANALYSIS BY ADMINISTRATION ROUTE
  176.   6.14 GERMANY MARKET ANALYSIS BY APPLICATION AREA
  177.   6.15 GERMANY MARKET ANALYSIS BY END USER
  178.   6.16 UK MARKET ANALYSIS BY DRUG CLASS
  179.   6.17 UK MARKET ANALYSIS BY ADMINISTRATION ROUTE
  180.   6.18 UK MARKET ANALYSIS BY APPLICATION AREA
  181.   6.19 UK MARKET ANALYSIS BY END USER
  182.   6.20 FRANCE MARKET ANALYSIS BY DRUG CLASS
  183.   6.21 FRANCE MARKET ANALYSIS BY ADMINISTRATION ROUTE
  184.   6.22 FRANCE MARKET ANALYSIS BY APPLICATION AREA
  185.   6.23 FRANCE MARKET ANALYSIS BY END USER
  186.   6.24 RUSSIA MARKET ANALYSIS BY DRUG CLASS
  187.   6.25 RUSSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  188.   6.26 RUSSIA MARKET ANALYSIS BY APPLICATION AREA
  189.   6.27 RUSSIA MARKET ANALYSIS BY END USER
  190.   6.28 ITALY MARKET ANALYSIS BY DRUG CLASS
  191.   6.29 ITALY MARKET ANALYSIS BY ADMINISTRATION ROUTE
  192.   6.30 ITALY MARKET ANALYSIS BY APPLICATION AREA
  193.   6.31 ITALY MARKET ANALYSIS BY END USER
  194.   6.32 SPAIN MARKET ANALYSIS BY DRUG CLASS
  195.   6.33 SPAIN MARKET ANALYSIS BY ADMINISTRATION ROUTE
  196.   6.34 SPAIN MARKET ANALYSIS BY APPLICATION AREA
  197.   6.35 SPAIN MARKET ANALYSIS BY END USER
  198.   6.36 REST OF EUROPE MARKET ANALYSIS BY DRUG CLASS
  199.   6.37 REST OF EUROPE MARKET ANALYSIS BY ADMINISTRATION ROUTE
  200.   6.38 REST OF EUROPE MARKET ANALYSIS BY APPLICATION AREA
  201.   6.39 REST OF EUROPE MARKET ANALYSIS BY END USER
  202.   6.40 APAC MARKET ANALYSIS
  203.   6.41 CHINA MARKET ANALYSIS BY DRUG CLASS
  204.   6.42 CHINA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  205.   6.43 CHINA MARKET ANALYSIS BY APPLICATION AREA
  206.   6.44 CHINA MARKET ANALYSIS BY END USER
  207.   6.45 INDIA MARKET ANALYSIS BY DRUG CLASS
  208.   6.46 INDIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  209.   6.47 INDIA MARKET ANALYSIS BY APPLICATION AREA
  210.   6.48 INDIA MARKET ANALYSIS BY END USER
  211.   6.49 JAPAN MARKET ANALYSIS BY DRUG CLASS
  212.   6.50 JAPAN MARKET ANALYSIS BY ADMINISTRATION ROUTE
  213.   6.51 JAPAN MARKET ANALYSIS BY APPLICATION AREA
  214.   6.52 JAPAN MARKET ANALYSIS BY END USER
  215.   6.53 SOUTH KOREA MARKET ANALYSIS BY DRUG CLASS
  216.   6.54 SOUTH KOREA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  217.   6.55 SOUTH KOREA MARKET ANALYSIS BY APPLICATION AREA
  218.   6.56 SOUTH KOREA MARKET ANALYSIS BY END USER
  219.   6.57 MALAYSIA MARKET ANALYSIS BY DRUG CLASS
  220.   6.58 MALAYSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  221.   6.59 MALAYSIA MARKET ANALYSIS BY APPLICATION AREA
  222.   6.60 MALAYSIA MARKET ANALYSIS BY END USER
  223.   6.61 THAILAND MARKET ANALYSIS BY DRUG CLASS
  224.   6.62 THAILAND MARKET ANALYSIS BY ADMINISTRATION ROUTE
  225.   6.63 THAILAND MARKET ANALYSIS BY APPLICATION AREA
  226.   6.64 THAILAND MARKET ANALYSIS BY END USER
  227.   6.65 INDONESIA MARKET ANALYSIS BY DRUG CLASS
  228.   6.66 INDONESIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  229.   6.67 INDONESIA MARKET ANALYSIS BY APPLICATION AREA
  230.   6.68 INDONESIA MARKET ANALYSIS BY END USER
  231.   6.69 REST OF APAC MARKET ANALYSIS BY DRUG CLASS
  232.   6.70 REST OF APAC MARKET ANALYSIS BY ADMINISTRATION ROUTE
  233.   6.71 REST OF APAC MARKET ANALYSIS BY APPLICATION AREA
  234.   6.72 REST OF APAC MARKET ANALYSIS BY END USER
  235.   6.73 SOUTH AMERICA MARKET ANALYSIS
  236.   6.74 BRAZIL MARKET ANALYSIS BY DRUG CLASS
  237.   6.75 BRAZIL MARKET ANALYSIS BY ADMINISTRATION ROUTE
  238.   6.76 BRAZIL MARKET ANALYSIS BY APPLICATION AREA
  239.   6.77 BRAZIL MARKET ANALYSIS BY END USER
  240.   6.78 MEXICO MARKET ANALYSIS BY DRUG CLASS
  241.   6.79 MEXICO MARKET ANALYSIS BY ADMINISTRATION ROUTE
  242.   6.80 MEXICO MARKET ANALYSIS BY APPLICATION AREA
  243.   6.81 MEXICO MARKET ANALYSIS BY END USER
  244.   6.82 ARGENTINA MARKET ANALYSIS BY DRUG CLASS
  245.   6.83 ARGENTINA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  246.   6.84 ARGENTINA MARKET ANALYSIS BY APPLICATION AREA
  247.   6.85 ARGENTINA MARKET ANALYSIS BY END USER
  248.   6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY DRUG CLASS
  249.   6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  250.   6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION AREA
  251.   6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER
  252.   6.90 MEA MARKET ANALYSIS
  253.   6.91 GCC COUNTRIES MARKET ANALYSIS BY DRUG CLASS
  254.   6.92 GCC COUNTRIES MARKET ANALYSIS BY ADMINISTRATION ROUTE
  255.   6.93 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION AREA
  256.   6.94 GCC COUNTRIES MARKET ANALYSIS BY END USER
  257.   6.95 SOUTH AFRICA MARKET ANALYSIS BY DRUG CLASS
  258.   6.96 SOUTH AFRICA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  259.   6.97 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION AREA
  260.   6.98 SOUTH AFRICA MARKET ANALYSIS BY END USER
  261.   6.99 REST OF MEA MARKET ANALYSIS BY DRUG CLASS
  262.   6.100 REST OF MEA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  263.   6.101 REST OF MEA MARKET ANALYSIS BY APPLICATION AREA
  264.   6.102 REST OF MEA MARKET ANALYSIS BY END USER
  265.   6.103 KEY BUYING CRITERIA OF HEALTHCARE
  266.   6.104 RESEARCH PROCESS OF MRFR
  267.   6.105 DRO ANALYSIS OF HEALTHCARE
  268.   6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  269.   6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  270.   6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
  271.   6.109 HEALTHCARE, BY DRUG CLASS, 2024 (% SHARE)
  272.   6.110 HEALTHCARE, BY DRUG CLASS, 2024 TO 2035 (USD Billion)
  273.   6.111 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 (% SHARE)
  274.   6.112 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Billion)
  275.   6.113 HEALTHCARE, BY APPLICATION AREA, 2024 (% SHARE)
  276.   6.114 HEALTHCARE, BY APPLICATION AREA, 2024 TO 2035 (USD Billion)
  277.   6.115 HEALTHCARE, BY END USER, 2024 (% SHARE)
  278.   6.116 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
  279.   6.117 BENCHMARKING OF MAJOR COMPETITORS
  280. 7 LIST OF TABLES
  281.   7.1 LIST OF ASSUMPTIONS
  282.     7.1.1
  283.   7.2 North America MARKET SIZE ESTIMATES; FORECAST
  284.     7.2.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  285.     7.2.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  286.     7.2.3 BY APPLICATION AREA, 2025-2035 (USD Billion)
  287.     7.2.4 BY END USER, 2025-2035 (USD Billion)
  288.   7.3 US MARKET SIZE ESTIMATES; FORECAST
  289.     7.3.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  290.     7.3.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  291.     7.3.3 BY APPLICATION AREA, 2025-2035 (USD Billion)
  292.     7.3.4 BY END USER, 2025-2035 (USD Billion)
  293.   7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  294.     7.4.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  295.     7.4.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  296.     7.4.3 BY APPLICATION AREA, 2025-2035 (USD Billion)
  297.     7.4.4 BY END USER, 2025-2035 (USD Billion)
  298.   7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  299.     7.5.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  300.     7.5.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  301.     7.5.3 BY APPLICATION AREA, 2025-2035 (USD Billion)
  302.     7.5.4 BY END USER, 2025-2035 (USD Billion)
  303.   7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  304.     7.6.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  305.     7.6.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  306.     7.6.3 BY APPLICATION AREA, 2025-2035 (USD Billion)
  307.     7.6.4 BY END USER, 2025-2035 (USD Billion)
  308.   7.7 UK MARKET SIZE ESTIMATES; FORECAST
  309.     7.7.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  310.     7.7.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  311.     7.7.3 BY APPLICATION AREA, 2025-2035 (USD Billion)
  312.     7.7.4 BY END USER, 2025-2035 (USD Billion)
  313.   7.8 France MARKET SIZE ESTIMATES; FORECAST
  314.     7.8.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  315.     7.8.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  316.     7.8.3 BY APPLICATION AREA, 2025-2035 (USD Billion)
  317.     7.8.4 BY END USER, 2025-2035 (USD Billion)
  318.   7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  319.     7.9.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  320.     7.9.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  321.     7.9.3 BY APPLICATION AREA, 2025-2035 (USD Billion)
  322.     7.9.4 BY END USER, 2025-2035 (USD Billion)
  323.   7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  324.     7.10.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  325.     7.10.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  326.     7.10.3 BY APPLICATION AREA, 2025-2035 (USD Billion)
  327.     7.10.4 BY END USER, 2025-2035 (USD Billion)
  328.   7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  329.     7.11.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  330.     7.11.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  331.     7.11.3 BY APPLICATION AREA, 2025-2035 (USD Billion)
  332.     7.11.4 BY END USER, 2025-2035 (USD Billion)
  333.   7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  334.     7.12.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  335.     7.12.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  336.     7.12.3 BY APPLICATION AREA, 2025-2035 (USD Billion)
  337.     7.12.4 BY END USER, 2025-2035 (USD Billion)
  338.   7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  339.     7.13.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  340.     7.13.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  341.     7.13.3 BY APPLICATION AREA, 2025-2035 (USD Billion)
  342.     7.13.4 BY END USER, 2025-2035 (USD Billion)
  343.   7.14 China MARKET SIZE ESTIMATES; FORECAST
  344.     7.14.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  345.     7.14.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  346.     7.14.3 BY APPLICATION AREA, 2025-2035 (USD Billion)
  347.     7.14.4 BY END USER, 2025-2035 (USD Billion)
  348.   7.15 India MARKET SIZE ESTIMATES; FORECAST
  349.     7.15.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  350.     7.15.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  351.     7.15.3 BY APPLICATION AREA, 2025-2035 (USD Billion)
  352.     7.15.4 BY END USER, 2025-2035 (USD Billion)
  353.   7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  354.     7.16.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  355.     7.16.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  356.     7.16.3 BY APPLICATION AREA, 2025-2035 (USD Billion)
  357.     7.16.4 BY END USER, 2025-2035 (USD Billion)
  358.   7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  359.     7.17.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  360.     7.17.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  361.     7.17.3 BY APPLICATION AREA, 2025-2035 (USD Billion)
  362.     7.17.4 BY END USER, 2025-2035 (USD Billion)
  363.   7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  364.     7.18.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  365.     7.18.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  366.     7.18.3 BY APPLICATION AREA, 2025-2035 (USD Billion)
  367.     7.18.4 BY END USER, 2025-2035 (USD Billion)
  368.   7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  369.     7.19.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  370.     7.19.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  371.     7.19.3 BY APPLICATION AREA, 2025-2035 (USD Billion)
  372.     7.19.4 BY END USER, 2025-2035 (USD Billion)
  373.   7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  374.     7.20.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  375.     7.20.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  376.     7.20.3 BY APPLICATION AREA, 2025-2035 (USD Billion)
  377.     7.20.4 BY END USER, 2025-2035 (USD Billion)
  378.   7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  379.     7.21.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  380.     7.21.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  381.     7.21.3 BY APPLICATION AREA, 2025-2035 (USD Billion)
  382.     7.21.4 BY END USER, 2025-2035 (USD Billion)
  383.   7.22 South America MARKET SIZE ESTIMATES; FORECAST
  384.     7.22.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  385.     7.22.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  386.     7.22.3 BY APPLICATION AREA, 2025-2035 (USD Billion)
  387.     7.22.4 BY END USER, 2025-2035 (USD Billion)
  388.   7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  389.     7.23.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  390.     7.23.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  391.     7.23.3 BY APPLICATION AREA, 2025-2035 (USD Billion)
  392.     7.23.4 BY END USER, 2025-2035 (USD Billion)
  393.   7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  394.     7.24.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  395.     7.24.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  396.     7.24.3 BY APPLICATION AREA, 2025-2035 (USD Billion)
  397.     7.24.4 BY END USER, 2025-2035 (USD Billion)
  398.   7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  399.     7.25.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  400.     7.25.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  401.     7.25.3 BY APPLICATION AREA, 2025-2035 (USD Billion)
  402.     7.25.4 BY END USER, 2025-2035 (USD Billion)
  403.   7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  404.     7.26.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  405.     7.26.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  406.     7.26.3 BY APPLICATION AREA, 2025-2035 (USD Billion)
  407.     7.26.4 BY END USER, 2025-2035 (USD Billion)
  408.   7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  409.     7.27.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  410.     7.27.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  411.     7.27.3 BY APPLICATION AREA, 2025-2035 (USD Billion)
  412.     7.27.4 BY END USER, 2025-2035 (USD Billion)
  413.   7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  414.     7.28.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  415.     7.28.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  416.     7.28.3 BY APPLICATION AREA, 2025-2035 (USD Billion)
  417.     7.28.4 BY END USER, 2025-2035 (USD Billion)
  418.   7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  419.     7.29.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  420.     7.29.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  421.     7.29.3 BY APPLICATION AREA, 2025-2035 (USD Billion)
  422.     7.29.4 BY END USER, 2025-2035 (USD Billion)
  423.   7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  424.     7.30.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  425.     7.30.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  426.     7.30.3 BY APPLICATION AREA, 2025-2035 (USD Billion)
  427.     7.30.4 BY END USER, 2025-2035 (USD Billion)
  428.   7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  429.     7.31.1
  430.   7.32 ACQUISITION/PARTNERSHIP
  431.     7.32.1

Healthcare Market Segmentation

Healthcare By Drug Class (USD Billion, 2025-2035)

  • NRTIs
  • NNRTIs
  • PIs
  • Integrase Inhibitors

Healthcare By Administration Route (USD Billion, 2025-2035)

  • Oral
  • Injection
  • Topical

Healthcare By Application Area (USD Billion, 2025-2035)

  • Pre-Exposure Prophylaxis
  • Post-Exposure Prophylaxis
  • Prevention in High-Risk Populations

Healthcare By End User (USD Billion, 2025-2035)

  • Hospitals
  • Clinics
  • Home Care Settings

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions